Companies in the Services sector have received a lot of coverage today as analysts weigh in on Humana Inc (HUM) and Evolent Health (EVH).
Humana Inc (HUM)
In a report released today, Steven Halper from Cantor Fitzgerald reiterated a Hold rating on Humana Inc, with a price target of $295. The company’s shares closed yesterday at $331.81, close to its 52-week high of $341.30.
Halper commented:
“We rate the shares of HUM at Neutral. The shares continue to trade above our price target of $295. We expect HUM to move ahead with its growth strategies in 2018, even though some challenges still exist. We appreciate the investments in healthcare services, which should help increase quality and lower costs to health plan members. $295 price target is supported by our DCF analysis. The Disclosure Section may be found on pages 3 – 4.Valuation Our $295 price target is supported by our DCF analysis.”
According to TipRanks.com, Halper is a top 100 analyst with an average return of 20.8% and a 69.8% success rate. Halper covers the Services sector, focusing on stocks such as WellCare Health Plans, Tivity Health Inc, and Hms Holdings Corp.
Humana Inc has an analyst consensus of Moderate Buy, with a price target consensus of $363.67.
See today’s analyst top recommended stocks >>
Evolent Health (EVH)
In a report released today, Mohan Naidu from Oppenheimer maintained a Buy rating on Evolent Health, with a price target of $31. The company’s shares closed yesterday at $22.86.
Naidu observed:
“EVH’s 3Q18 numbers were well ahead of our and consensus estimates on strong services revenues. New Century Health adds nicely to numbers and moves estimates higher for Q4. The company announced several positive data points with customer opportunities and confidence on the proposed CMS ruling to push 2-sided risk aggressively. Since the comment period ended last month, we expect to see a final ruling from CMS that puts a finite timing on the move toward 2-sided risk, which will be a strong tailwind for EVH. Further, work on the Medicaid side is starting to pay off with several clients. We continue to be encouraged by the momentum in the transition toward risk-based reimbursement and by EVH’s position to gain from it. Reiterate Outperform, $31 target.”
According to TipRanks.com, Naidu is a 5-star analyst with an average return of 15.5% and a 61.3% success rate. Naidu covers the Services sector, focusing on stocks such as Tivity Health Inc, Hms Holdings Corp, and Premier Inc.
Currently, the analyst consensus on Evolent Health is a Strong Buy with an average price target of $32.67, a 42.9% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $37 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
